fair enough - I think manufacturing shouldn’t be an issue. It clearly has the advantage in that area. I think it’s more the logistics and supply chain of the drug that will make it tricky to commercialise. It has a longer half life but it is still time sensitive.
Personally, it’s not something that I know too much about but that would definitely be something Pharma companies will look for as well as the manufacturing.
Research/Valuation, page-5
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.04 |
Change
0.080(2.02%) |
Mkt cap ! $1.252B | |||
| Open | High | Low | Value | Volume |
| $3.97 | $4.08 | $3.81 | $3.404M | 859.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2466 | $4.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.06 | 925 | 1 |
View Market Depth
| Last trade - 10.49am 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.03 |
Change
0.080 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| $4.00 | $4.13 | $3.81 | 48833 | ||
| Last updated 11.09am 10/05/2024 ? | |||||
| CU6 (ASX) Chart |